☆ 4.6 Article

mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients

LIFE SCIENCE ALLIANCE (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals

Ai-ris Y. Collier et al.

Summary: Individuals on immunosuppressive therapy exhibit impaired immune responses to COVID-19 mRNA vaccination, reducing their ability to develop protective immunity. This suggests that standard COVID-19 mRNA vaccine regimens may not offer optimal protection for immunocompromised individuals.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Cell Biology

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals

Marie Samanovic et al.

Summary: COVID-19 vaccines are crucial in ending the pandemic, but the immune responses induced by mRNA vaccines may differ in individuals who had recovered from COVID-19. The study found that both groups exhibited robust cytotoxic T cell responses after the second dose of the vaccine. However, individuals with no prior COVID-19 infection had increasing humoral and antigen-specific antibody-secreting cell responses after each dose, while those who had recovered from COVID-19 showed strong initial responses that did not further enhance after the second dose.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Rheumatology

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Satveer K. Mahil et al.

Summary: Patients receiving methotrexate may have impaired humoral immunity to a single dose of the BNT162b2 vaccine, but not those receiving targeted biologics. Cellular immune responses are preserved in all groups. Real-world pharmacovigilance studies are needed to determine the clinical effectiveness of these findings.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medical Laboratory Technology

Evaluation of the automated LIAISON (R) SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies

Fabrizio Bonelli et al.

Summary: COVID-19 has led to an influx of tests from various manufacturers, with immunoassays playing a key role in epidemiological studies, longitudinal immunity understanding, and vaccine development. Evaluation of the LIAISON (R) SARS-CoV-2 TrimericS IgG assay demonstrated high sensitivity and specificity, making it suitable for use in high prevalence populations.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal et al.

Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.

EUROSURVEILLANCE (2021)

Add to Collection

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times

Thomas Bachelet et al.

Summary: Dialysis patients are both most likely to benefit from COVID-19 vaccination but also at high risk of not developing an immune response. Immunocompromised status, age, medical history, and inflammatory markers are all associated with the immune response to the vaccine.

PLOS ONE (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients

Cong Zeng et al.

Summary: Cancer patients, especially those with CLL and NHL, exhibit lower neutralizing antibody responses after receiving two doses of mRNA vaccines, indicating an urgent need for novel immunization strategies against SARS-CoV-2.

CELL AND BIOSCIENCE (2021)

Add to Collection

Letter Immunology

Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents

Jens T. Van Praet et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Prabhu S. Arunachalam et al.

Summary: This study demonstrated the effectiveness of an adjuvanted RBD-NP vaccine in inducing robust and durable neutralizing antibody responses, providing protection against SARS-CoV-2 infection, and cross-neutralizing various variants. Adjuvants such as AS03 and AS37 significantly enhanced the immunogenicity of the vaccine and have the potential to be candidates for COVID-19 vaccines.

NATURE (2021)

Add to Collection

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

Add to Collection

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee Greenberger et al.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

Add to Collection

Article Urology & Nephrology

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Clement Danthu et al.

Summary: The study shows that kidney transplant recipients have a strong inhibition of humoral response to COVID-19 vaccination due to immunosuppressant therapy, while patients undergoing hemodialysis have lower antibody levels. Factors such as age, serum albumin, and Kt/V can impact the level of antibody response.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Prabhu S. Arunachalam et al.

Summary: The study found that vaccination with the Pfizer-BioNTech mRNA vaccine can induce immune responses against neutralizing antibodies and CD4, CD8 T cells of SARS-CoV-2. Booster vaccines can significantly enhance innate immune responses, and different innate pathways associated with CD8 T cells and neutralizing antibodies have been identified.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange et al.

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021

Heather M. Scobie et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Microbiology

Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays

Thomas Perkmann et al.

Summary: Reliable quantification of the antibody response to SARS-CoV-2 is crucial for identifying possible vaccine failure and estimating protection time. Despite good overall agreement, the performance of five antibody quantification assays showed differences that highlight the need for further standardization of SARS-CoV-2 serology.

MICROBIOLOGY SPECTRUM (2021)

Add to Collection

Article Oncology

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

David J. Chung et al.

Summary: Patients with hematologic malignancy have compromised COVID-19 vaccine responses at baseline, which are further suppressed by certain therapies, leading to insufficient neutralizing capacity despite positive antibody titers. Refining vaccine response parameters is critical for guiding clinical care, including the consideration for booster vaccines in this vulnerable population.

BLOOD CANCER DISCOVERY (2021)

Add to Collection

Article Medicine, Research & Experimental

One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19

Riccardo Levi et al.

Summary: A study showed that individuals with prior exposure to SARS-CoV-2 had a significant increase in antibody response within 5 to 18 days after receiving the Pfizer/BioNTech vaccine. Symptomatic individuals reached a high titer of antibodies with just one dose, suggesting that a second dose may not be necessary.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Oncology

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Astha Thakkar et al.

Summary: The study found differential rates of SARS-CoV-2 IgG seroconversion in cancer patients based on specific cancer types and therapy modalities. Patients with hematological malignancies, those receiving anti-CD-20 antibody therapy, and stem cell transplant patients had significantly lower seroconversion rates, while patients receiving immunotherapy, especially anti-PD-1/PD-L1 monoclonal antibodies, showed 100% seroconversion rates. These findings have implications for clinical monitoring and vaccination strategies to combat the COVID-19 pandemic.

NATURE CANCER (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Chee Wah Tan et al.

NATURE BIOTECHNOLOGY (2020)

Add to Collection

Article Oncology

Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

David J. Pinato et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.